| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005462977 |
| P356 | DOI | 10.1038/ONC.2015.338 |
| P698 | PubMed publication ID | 26364597 |
| P2093 | author name string | T Wang | |
| Y Ito | |||
| Y Chen | |||
| S J Lin | |||
| M Sudol | |||
| S C Lee | |||
| P Tan | |||
| F Zhu | |||
| Y Qiao | |||
| K G Yeoh | |||
| L S H Chuang | |||
| D C-C Voon | |||
| P2860 | cites work | Role of scaffold protein afadin dilute domain-interacting protein (ADIP) in platelet-derived growth factor-induced cell movement by activating Rac protein through Vav2 protein | Q24294652 |
| Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control | Q24299106 | ||
| YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response | Q24299975 | ||
| RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis | Q24310469 | ||
| SMARCA3, a chromatin-remodeling factor, is required for p11-dependent antidepressant action | Q24317422 | ||
| Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein | Q24323326 | ||
| The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules | Q24323939 | ||
| TEAD mediates YAP-dependent gene induction and growth control | Q24336045 | ||
| A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer | Q24337135 | ||
| Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma | Q24339585 | ||
| A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator | Q24534123 | ||
| Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of TEAD4 in gastric cancer | Q39044714 | ||
| YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. | Q39096242 | ||
| Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity | Q39296192 | ||
| YAP regulates neuronal differentiation through Sonic hedgehog signaling pathway | Q39338017 | ||
| Phosphorylation of the gastric tumor suppressor RUNX3 following H. pylori infection results in its localization to the cytoplasm. | Q39543664 | ||
| Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation | Q39672903 | ||
| Fold change rank ordering statistics: a new method for detecting differentially expressed genes. | Q41887389 | ||
| The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. | Q52605847 | ||
| Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects. | Q52652395 | ||
| Calpain 6 supports tumorigenesis by inhibiting apoptosis and facilitating angiogenesis. | Q53318971 | ||
| G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer. | Q54358159 | ||
| Gastric cancer | Q80681392 | ||
| Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF | Q83473383 | ||
| Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes | Q83831946 | ||
| Gastric cancer--an enigmatic and heterogeneous disease | Q84156232 | ||
| The evolution of antibodies into versatile tumor-targeting agents | Q95805864 | ||
| Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP | Q24594281 | ||
| Hippo pathway-independent restriction of TAZ and YAP by angiomotin | Q24614424 | ||
| TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm | Q24632716 | ||
| Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP | Q28241192 | ||
| Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product | Q28245300 | ||
| The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP | Q28266862 | ||
| Whole-genome analysis informs breast cancer response to aromatase inhibition | Q28269291 | ||
| Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain | Q28272433 | ||
| The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version | Q28281214 | ||
| The WW domain: a signalling site in dystrophin? | Q28306741 | ||
| Causal relationship between the loss of RUNX3 expression and gastric cancer | Q28509530 | ||
| Role of YAP/TAZ in mechanotransduction | Q29615411 | ||
| Elucidation of a universal size-control mechanism in Drosophila and mammals | Q29618935 | ||
| RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. | Q33883483 | ||
| KRAS and YAP1 converge to regulate EMT and tumor survival | Q33946244 | ||
| Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis | Q34002911 | ||
| RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. | Q34042783 | ||
| Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway | Q34444831 | ||
| The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis | Q34718167 | ||
| Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination | Q35339610 | ||
| YAP oncogene overexpression supercharges colon cancer proliferation | Q35911150 | ||
| Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis | Q35987073 | ||
| The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain | Q36236290 | ||
| RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells | Q36413997 | ||
| SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma | Q36691348 | ||
| Identification of RUNX3 as a component of the MST/Hpo signaling pathway | Q36784391 | ||
| RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α | Q36971996 | ||
| Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription | Q37259684 | ||
| Oncogenic pathway combinations predict clinical prognosis in gastric cancer. | Q37357165 | ||
| VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex | Q37623587 | ||
| RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes | Q38118553 | ||
| The RUNX family: developmental regulators in cancer | Q38319972 | ||
| VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer | Q38907612 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2664-2674 | |
| P577 | publication date | 2015-09-14 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer | |
| P478 | volume | 35 |
| Q52562248 | A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. |
| Q90233046 | Activating Hippo Pathway via Rassf1 by Ursolic Acid Suppresses the Tumorigenesis of Gastric Cancer |
| Q90707399 | Corosolic acid inhibits cancer progress through inactivating YAP in hepatocellular carcinoma |
| Q49797899 | DNA binding partners of YAP/TAZ. |
| Q38637679 | Emerging role of Hippo signalling pathway in bladder cancer |
| Q45044138 | Generation of RUNX3 knockout pigs using CRISPR/Cas9-mediated gene targeting |
| Q91808467 | Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck |
| Q90142330 | Homeobox A4 suppresses vascular remodeling by repressing YAP/TEAD transcriptional activity |
| Q42700861 | Identification of a novel YAP-14-3-3ζ negative feedback loop in gastric cancer |
| Q64064070 | Identification of exosomal and non‑exosomal microRNAs associated with the drug resistance of ovarian cancer |
| Q64082785 | New Therapeutic Approach for Targeting Hippo Signalling Pathway |
| Q52369044 | PIWIL1/piRNA-DQ593109 Regulates the Permeability of the Blood-Tumor Barrier via the MEG3/miR-330-5p/RUNX3 Axis. |
| Q36079567 | RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3. |
| Q55262723 | RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. |
| Q50290763 | RUNX3 binds TEADs and YAP1 |
| Q45316834 | RUNX3 regulates YAP1-mediated transcription |
| Q49853226 | Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway. |
| Q28066930 | Repair Injured Heart by Regulating Cardiac Regenerative Signals |
| Q47944350 | Roles of RUNX in Hippo Pathway Signaling. |
| Q50796410 | Roles of RUNX in Solid Tumors. |
| Q47126606 | TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. |
| Q50290764 | TEADs:YAP1 binds CTGF gene |
| Q42378384 | The prognostic impacts of TEA domain (TEAD) transcription factor polymorphisms in Chinese hepatocellular carcinoma patients |
| Q37190507 | Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer |
| Q45316828 | Transcriptional regulation by RUNX3 |
| Q41389363 | YAP signaling in gastric cancer-derived mesenchymal stem cells is critical for its promoting role in cancer progression |
Search more.